| CPC A61K 31/555 (2013.01) [A61K 31/198 (2013.01); A61K 31/4196 (2013.01); A61K 31/635 (2013.01); A61K 31/655 (2013.01); A61K 31/70 (2013.01); A61K 31/7135 (2013.01); A61K 33/242 (2019.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01)] | 21 Claims |
|
1. A method of treating a cancer in a mammalian subject afflicted therewith, the cancer being selected from the group consisting of breast cancer, and lung cancer, the method comprising:
administering to the subject at least one active agent comprising a thioredoxin reductase inhibitor;
wherein the thioredoxin reductase inhibitor is auranofin; and
administering to the subject a pentaaza macrocyclic ring complex corresponding to formulae (II), (III) or (IV) below:
![]() wherein
X and Y are independently selected from any one or more of: (i) the group consisting of fluoro, chloro, bromo, and iodo anions; (ii) the group consisting of alkyl carboxylates, aryl carboxylates and arylalkyl carboxylates; and (iii) amino acids; and
RA, RB, RC, and RD are independently hydrogen or hydrocarbyl.
|